Description: ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in are areas of cell-based therapy, cancer, and stem cell research, development, and manufacturing of pharmaceuticals as well as production and quality control of animal semen and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter SP-100, an automated sperm cell counter for use in animal production; NucleoCounter SCC-100, a somatic cell counter used to measure the number of somatic cells in a milk sample; and NucleoCounter YC-100, an automated yeast cell counter used to measure the total cell count and viability of yeast cells in suspension. It also provides consumables comprising cassettes, reagents, and slides; accessories, which include cables, power supplies, software, and labware products, as well as service and validation plans. The company was incorporated in 1997 and is headquartered in Allerød, Denmark.
Home Page: chemometec.com
Gydevang 43
Allerød,
3450
Denmark
Phone:
45 48 13 10 20
Officers
Name | Title |
---|---|
Mr. Hans Martin Glensbjerg | Vice Chairman & COO |
Mr. Steen Sondergaard | Chief Exec. Officer |
Niels Hoy Nielsen | Chief Financial Officer |
Ms. Lisbet Helles | Head of Marketing |
Mr. Søren Kjærulff | Head of R&D |
Mr. Michael Packert | Head of Production |
Mr. Christopher Runchel M.Sc., Ph.D. | Sr. VP of US |
Mr. Martin Helbo Behrens | Chief Financial Officer of US |
Exchange: CO
Country: DK
Currency: Danish krone (kr)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Life Sciences Tools & Services |
GIC Sub-Industry: | Life Sciences Tools & Services |
Forward PE: | 0 |
---|---|
Trailing PE: | 73.1327 |
Price-to-Book MRQ: | 40.8261 |
Price-to-Sales TTM: | 32.0974 |
IPO Date: | 2006-12-18 |
Fiscal Year End: | June |
Full Time Employees: | 155 |